Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLOTYN vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Relapsed or refractory peripheral T-cell lymphoma (PTCL)
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Pralatrexate is primarily metabolized via hepatic metabolism; specific enzymes not fully characterized. It is not a significant substrate for CYP450 enzymes.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Approximately 67% bound to human plasma proteins, primarily albumin.
Approximately 20–30% bound to plasma proteins.
Volume of distribution at steady state is approximately 0.5 L/kg (range 0.3–0.7 L/kg), indicating distribution into total body water with some tissue binding.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Only intravenous administration is approved; oral bioavailability has not been established (not for oral use).
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No specific dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Child-Pugh A: 2.0 mg/m2. Child-Pugh B: 1.5 mg/m2. Child-Pugh C: not recommended.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Not approved for pediatric use; safety and efficacy not established.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustments; monitor for renal function and toxicity as elderly patients may have reduced organ function.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: FOLOTYN may cause severe or fatal mucositis, thrombocytopenia, and other hematologic toxicities. Administer with close monitoring, and manage with dose modifications and supportive care as needed.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Mucositis, hematologic toxicity (including thrombocytopenia, neutropenia, anemia), dermatologic reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), tumor lysis syndrome, hepatotoxicity, and renal toxicity. Monitor complete blood counts, liver function, renal function, and mucositis. Dose adjustments required for toxicity.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Hypersensitivity to pralatrexate or any component of the formulation.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction leading to increased toxicity. No other specific food restrictions.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
FOLOTYN (pralatrexate) is a folate analog metabolic inhibitor; based on its mechanism of action and animal studies, it is expected to cause fetal harm when administered to a pregnant woman. In animal reproduction studies, pralatrexate caused embryo-fetal toxicity and malformations at doses below the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Advise pregnant women of the potential risk to a fetus. During first trimester: high risk of teratogenicity (neural tube defects, cardiovascular malformations). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and fetal death.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
No data are available regarding the presence of pralatrexate in human milk, effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with FOLOTYN and for at least 1 week after the last dose. M/P ratio: unknown.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
Physiologic changes in pregnancy can alter drug pharmacokinetics, but there are no established dosing guidelines for FOLOTYN during pregnancy. Dose adjustments should be based on toxicity monitoring (e.g., mucositis, myelosuppression). Due to potential for teratogenicity, avoid use in pregnancy unless benefit outweighs risk. No specific dose adjustments recommended for pregnancy alone.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Administer intramuscularly; rotate injection sites. Premedicate with corticosteroid, antihistamine, and antipyretic to reduce infusion reactions. Monitor for tumor lysis syndrome, hepatotoxicity, and myelosuppression. Dose adjustment required for renal impairment (Cr Cl <50 m L/min). Contraindicated in pregnancy.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
This medicine is given as an injection into a muscle, usually once weekly.,You may receive medications before your dose to prevent allergic reactions.,Report any signs of infection, unusual bleeding, or bruising promptly.,Avoid pregnancy during treatment; use effective contraception.,Limit alcohol intake to reduce liver strain.,Avoid grapefruit and grapefruit juice as they may increase side effects.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLOTYN vs CLADRIBINE, answered by our medical review team.
FOLOTYN is a Antineoplastic Agent that works by FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLOTYN and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLOTYN is: 3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLOTYN and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLOTYN is classified as Category C. FOLOTYN (pralatrexate) is a folate analog metabolic inhibitor; based on its mechanism of action and animal studies, it is expected to cause fetal harm when administered to a pregna. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.